NMRA · Neumora Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“the current available cash and cash equivalents will not be sufficient to fund the Company’s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Positioning
Aug 21, 2026 · 4 days to expiryChain
Click any strike for greeks, breakeven and the calculator| Calls | Puts | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| OI | Vol | IV | Δ | Last | Strike | Last | Δ | IV | Vol | OI |
| 0 | — | 335.1% | 0.924 | — | $0.20 | — | — | 1 | 2 | |
| 7 | 1 | 654% | 0.677 | $0.25 | $0.13 | -0.346 | 207% | 13 | 11 | |
| 75 | 5 | 310.7% | 0.323 | $0.05 | $0.50 | -0.84 | 182.9% | 6.2k | 6.2k | |
| 87 | 1 | 440% | 0.259 | $0.35 | — | — | — | — | 0 | |
| 1 | 1 | — | — | $0.01 | — | — | — | — | 0 | |
| 0 | — | — | — | — | — | -0.776 | 1025.3% | — | 0 | |
About this data
Each contract's last price, volume, greeks, implied volatility and open interest belongs to the snapshot session shown in its details; unknown means the provider omitted the timestamp. This chain has mixed snapshot sessions · Jul 1, 2026–Aug 12, 2026; 5 unknown. Cross-contract positioning totals are shown only when every returned row has the same known session. Bid and ask are not included on this plan.
In-the-money strikes are tinted, deepening toward the money, and the bar beside each open-interest figure scales to the heaviest strike shown.